Happy Monday! Washington’s health agenda is moving fast this week — and the clashes aren’t staying confined to Capitol Hill. From a high-stakes surgeon general confirmation fight to escalating vaccine-policy fallout in the states, the administration’s priorities are colliding with Senate oversight, litigation, and industry pushback. Meanwhile, payment and regulatory decisions are forcing major health and food players to recalibrate in real time. Here’s what we are tracking.

In this week’s Nimitz Health:

• Federal News: Casey Means confirmation outlook, ACIP shakeup, MAHA vs. EPA on glyphosate, and movement on Senate HELP bills

• State News: Multi-state lawsuit over CDC vaccine guidance, Minnesota Medicaid funding freeze, H5N1 impacts on California coastal tourism, and public health concerns with data center emissions

• Industry News: Medicare Advantage payment fight, Food industry pushback on MAHA agenda, and recalls to watch out for

WHO’S HAVING EVENTS THIS WEEK?

Thursday, March 5th

• *Senate HELP: “Transforming Health Care with Data: Improving Patient Outcomes Through Next-Generation Care” at 10am. Watch here.

*Will be covered by Nimitz Health. Please email [email protected] if you would like a readout of any other hearings.

Sign up for The Nimitz Report for Veteran Health-Related Hearings

NEWS DRIVING THE WEEK

Federal News

The Senate HELP Committee is again at the center of the administration’s public-health fights. Surgeon general nominee Casey Means faced sharp questions on vaccines, her qualifications, and her influencer career; she repeatedly framed vaccination as “supportive” but emphasized “shared decision-making,” and senators pressed her on prior statements (including about the hep B birth dose) and on undisclosed/paid endorsements. Means’ confirmation remains uncertain: key Republicans Susan Collins and Lisa Murkowski have not committed, and HELP’s narrow partisan balance means even a single GOP defection could stall her.

HHS Secretary Robert F. Kennedy Jr. continued reshaping vaccine policymaking by naming two new members to the CDC’s Advisory Committee on Immunization Practices (ACIP), including a pediatrician who has publicly argued the Covid-19 vaccine should be pulled from the market. The appointments come as ACIP is slated to discuss Covid-19 vaccine issues soon and after prior leadership changes to the panel.

The administration’s “MAHA” agenda is also colliding with farm and chemical policy. After President Trump signed an executive order promoting glyphosate, MAHA activists are trying to leverage EPA’s upcoming glyphosate review to push for a more independent scientific process and less reliance on industry-funded studies. Agriculture Secretary Brooke Rollins is trying to steady relations with MAHA-aligned supporters, arguing the alliance is “unchanged” and framing the glyphosate move as a national security priority—despite grassroots backlash and threats of primaries.

On Capitol Hill, HELP did manage one bipartisan bright spot: the committee advanced a living organ donor protections bill and a health care cybersecurity bill by 22–1 votes, teeing them up for potential floor action.

State News

The clearest state-level flashpoint is the growing legal and political fallout from the administration’s vaccine posture. California and Arizona (joined by 13 other states) sued the Trump administration over CDC guidance that downgraded or shifted several childhood vaccine recommendations to “shared clinical decision-making,” and they also challenged Kennedy’s ACIP shakeup—arguing states rely heavily on those federal recommendations for coverage and school requirements.

Meanwhile, Minnesota remains ground zero for the White House’s Medicaid fraud crackdown. Vice President JD Vance launched his new “war on fraud” role by announcing a nearly $260 million Medicaid funding moratorium for the state, and outside experts warned the approach is atypical because it is not tied to a specific audit process the state can dispute. Minnesota officials framed the action as political retribution, while analysts noted the freeze is modest relative to total spending but still meaningful for a program that represents a major share of the state budget.

Two other state/local health notes from the week: California parks officials halted elephant seal tours at Año Nuevo State Park after H5N1 was confirmed in several weaned pups, underscoring the ongoing spillover concerns around highly pathogenic avian influenza. And a report out of Ohio highlighted potential respiratory impacts from data center-related air pollution, arguing that emissions (including nitrogen dioxide and fine particles) and backup diesel generators can pose health risks and urging states to require public health assessments before new complexes are built.

Industry News

Health industry stakeholders are bracing for several high-dollar federal decisions. Medicare Advantage insurers are pushing CMS to revise its proposed 0.09% 2027 payment update, arguing it would translate into flat funding and could drive benefit cuts and higher costs for seniors; plans want more transparency on the assumptions behind growth rates and on technical choices in the risk model.

The food sector is also turning up the pressure on the administration. Major manufacturers and trade groups—longtime GOP allies—are warning Trump that Kennedy’s MAHA-driven ingredient agenda (including tighter scrutiny of additives and a growing patchwork of state laws) could raise costs and disrupt supply chains; industry is calling for a single national standard and is funding messaging campaigns to make the economic case. At the same time, Kennedy previewed further moves aimed at the food system, including efforts to overhaul the GRAS pathway and push medical schools to expand nutrition training.

On the product safety front, FDA-related recalls continued to pile up. Walmart recalled Great Value cottage cheese sold in 24 states over concerns that certain liquid dairy ingredients may not have been fully pasteurized (no illnesses reported as of Feb. 24), and a separate recall targeted nearly 60,000 pounds of frozen blueberries later labeled Class I—FDA’s most serious risk category—over possible listeria contamination (distributed in multiple states, not sold directly at retail).

Finally, a few noteworthy research-and-market signals: a single-pill HIV regimen combining bictegravir and lenacapavir performed comparably to multi-pill therapy in a large international study, potentially simplifying care for older patients and those with resistance—an advance arriving amid broader global health funding pressures. And Financial Times reporting flagged how the “longevity/wellness” economy is accelerating demand for largely unproven peptide products marketed as “research chemicals,” even as experts warn the human evidence base is thin and risks are not well characterized.

FOR FUN

March is Brain Injury Awareness Month! Read more about symptoms, impact, prevention, and more here.

JOIN THE NIMITZ NETWORK!

Enjoying our updates? Don’t keep it to yourself — forward this email to friends or colleagues who’d love to stay informed. Please subscribe to our other publications by clicking below: